A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis

Inclusion Criteria: * Adult patients, 18 to 65 years of age inclusive * Patients with chronic kidney disease Stage III-IV not on dialysis * Hb \< 10 g/dL (for correction of anemia) or Hb 10-12 g/dL and receiving any other ESA (for maintenance of Hb levels) * Adequate iron status as judged by the treating physician Exclusion Criteria: * Hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication * Significant acute or chronic bleeding * Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types) * Active malignant disease during the last five years (except non-melanoma skin cancer) * Uncontrolled or symptomatic secondary hyperparathyroidism * Epileptic seizure during the last 6 months * Poorly controlled hypertension (sitting blood pressure \> 170/100 mmHG) * Myocardial infarction or stroke, or severe or unstable CAD * Severe liver disease during the previous 6 months * Congestive heart failure NYHA Class III-IV * Diagnosis or suspicion of pure red cell aplasia (PRCA) * Planned elective surgery during the study period (except cataract surgery and vascular access surgery) * Transfusion of red blood cells during the previous 2 months * Pregnant women * Any contra-indications to Mircera